Novel Mechanistic Interplay between Products of Oxidative Stress and Components of the Complement System in AMD Pathogenesis.
Age-related macular degeneration (AMD) is a leading cause of vision loss affecting tens of millions of elderly worldwide. Early AMD includes soft drusen and pigmentary changes in the retinal pigment epithelium (RPE). As people age, such soft confluent drusen can progress into two forms of advanced AMD, geographic atrophy (GA, or dry AMD) or choroidal neovascularization (CNV, or wet AMD) and result in the loss of central vision. The exact mechanism for developing early AMD and progressing to advanced stage of disease is still largely unknown. However, significant evidence exists demonstrating a complex interplay of genetic and environmental factors as the cause of AMD progression. Together, complement factor H (CFH) and HTRA1/ARMS polymorphisms contribute to more than 50% of the genetic risk for AMD. Environmentally, oxidative stress from activities such as smoking has also demonstrated a powerful contribution to AMD progression. To extend our previous finding that genetic polymorphisms in CFH results in OxPLs and the risk-form of CFH (CFH Y402H) has reduced affinity for oxidized phospholipids, and subsequent diminished capacity which subsequently diminishes the capability to attenuate the inflammatory effects of these molecules, we compared the binding properties of CFH and CFH related protein 1 (CFHR1), which is also associated with disease risk, to OxPLs and their effects on modulating inflammation and lipids uptake. As both CFH-402H and CFHR1 are associated with increased risk to AMD, we hypothesized that like CFH-402H, CFHR1 contribution to AMD risk may also be due to its diminished affinity for OxPLs. Interestingly, we found that association of CFHR1 with OxPLs was not statistically different than CFH. However, binding of CFHR1 did not elicit the same protective benefits as CFH in that both inflammation and lipid uptake are unaffected by CFHR1 association with OxPLs. These findings demonstrate a novel and interesting complexity to the potential interplay between the complement system and oxidative stress byproducts, such as OxPLs, in the mechanistic contribution to AMD. Future work will aim to identify the molecular distinctions between CFH and CFHR1 which confer protection by the former, but not latter molecules. Understanding the molecular domains necessary for protection could provide interventional insights in the generation of novel therapeutics for AMD and other diseases associated with oxidative stress.
Department of Ophthalmology, Xijing Hospital, Xi'an, China; Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, San Diego, USA.
Hongjun
H
Du
Sichuan Provincial People's Hospital, Chengdu, China.
Xu
X
Xiao
Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, San Diego, USA.
Travis
T
Stiles
Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, San Diego, USA.
Christopher
C
Douglas
Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, San Diego, USA.
Daisy
D
Ho
Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, San Diego, USA.
Peter X
PX
Shaw
Age-Related Macular Degeneration; Complement Factor H; Inflammation; Oxidative Stress
Surv Ophthalmol. 2000 Sep-Oct;45(2):115-34
11033038
N Engl J Med. 2008 Jun 12;358(24):2606-17
18550876
Mol Aspects Med. 2012 Aug;33(4):399-417
22510306
Ann N Y Acad Sci. 2001 Dec;947:214-22; discussion 222-3
11795269
Physiology (Bethesda). 2010 Feb;25(1):8-15
20134024
Adv Exp Med Biol. 2016;854:103-9
26427400
Arch Ophthalmol. 2004 Apr;122(4):564-72
15078675
Invest Ophthalmol Vis Sci. 2010 Feb;51(2):637-42
19797219
Arteriosclerosis. 1990 May-Jun;10 (3):325-35
1693068
Clin J Am Soc Nephrol. 2013 Mar;8(3):407-15
23243267
Arterioscler Thromb Vasc Biol. 2001 Aug;21(8):1333-9
11498462
Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13757-62
22875704
Adv Exp Med Biol. 2016;854:3-9
26427386
Chem Res Toxicol. 2011 Nov 21;24(11):1803-16
21875030
J Clin Invest. 1955 Sep;34(9):1345-53
13252080
Invest Ophthalmol Vis Sci. 2011 Jun 28;52(7):4663-70
21447678
Mol Vis. 2007 May 23;13:772-8
17563727
Cell Cycle. 2007 May 2;6(9):1122-5
17426452
J Am Coll Cardiol. 2011 Oct 11;58(16):1715-27
21982317
Mol Vis. 1999 Nov 03;5:25
10562649